Skip to main content
Erschienen in: Annals of Surgical Oncology 3/2007

01.03.2007

Monitoring Health Outcomes Following Cytoreductive Surgery Plus Intraperitoneal Hyperthermic Chemotherapy for Peritoneal Carcinomatosis

verfasst von: Richard P. McQuellon, Suzanne C. Danhauer, Gregory B. Russell, Perry Shen, Joyce Fenstermaker, John H. Stewart, Edward A. Levine

Erschienen in: Annals of Surgical Oncology | Ausgabe 3/2007

Einloggen, um Zugang zu erhalten

Abstract

Background

Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for peritoneal carcinomitosis (PC) is an aggressive treatment designed to alleviate symptoms and prolong life. It is associated with physical and psychological morbidity. The purpose of this study was to monitor health outcomes related to treatment.

Methods

Patients completed a questionnaire before and after surgery at 3, 6 and 12 months. The questionnaire consisted of basic demographic items as well as the Functional Assessment of Cancer Therapy–Colon Scale (FACT-C), SF-36 Medical Outcomes Study Health Survey, Center for Epidemiologic Studies–Depression Scale (CES-D), Brief Pain Inventory–Short Form, and ECOG Performance Status Rating. Time trends were assessed with mixed models (SAS PROC MIXED) so as to use all data and to account for missing data.

Results

Ninety-six patients (49% females, 9% African Americans) of an average age of 52.9 (SD = 12.5) years were assessed before surgery. PC originated in primary lesions of the appendix (n = 36); colon/rectum (n = 24); mesothelium (n = 9); ovary (n = 5); stomach (n = 4); and miscellaneous (n = 18). Quality of life (QOL) and pain scores improved from baseline to 12 months. Physical functioning changed over the 12-month study period with improvement recorded at 6 months. The percentage of patients reporting significant depressive symptom at each time point was; baseline= 32%; 3 months= 19%; 6 & 12 months= 24%.

Conclusions

Acceptable QOL, return of functional status, and reduced pain can be attained between 3 and 6 months following treatment although some deficits in general health remain. Depressive symptoms are common and should be monitored.
Literatur
1.
Zurück zum Zitat Spratt J, Edwards E, Kubata T, Linberg R, Tseng M. Peritoneal carcinometosis: anatomy, physiology, diagnosis, management. Curr Probl Cancer 1986; 558–84 Spratt J, Edwards E, Kubata T, Linberg R, Tseng M. Peritoneal carcinometosis: anatomy, physiology, diagnosis, management. Curr Probl Cancer 1986; 558–84
2.
Zurück zum Zitat Stewart JH, Shen P, Levine EA. Intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: current status and future directions. Ann Surg Oncol 2005; 12(10)765–77PubMedCrossRef Stewart JH, Shen P, Levine EA. Intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: current status and future directions. Ann Surg Oncol 2005; 12(10)765–77PubMedCrossRef
3.
Zurück zum Zitat Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J, et al. The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol 1993; 11:570–9PubMed Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J, et al. The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol 1993; 11:570–9PubMed
4.
Zurück zum Zitat Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85:365–76PubMedCrossRef Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85:365–76PubMedCrossRef
5.
Zurück zum Zitat McQuellon RP, Loggie BW, Fleming RA, Russell GB, Rambo TD, Biesecker AC, Craven B. Quality of life and functional status after intraperitoneal hyperthermic chemotherapy (IPHC) for peritoneal carcinomatosis. Eur J Surg Oncol 2001; 27:65–73PubMedCrossRef McQuellon RP, Loggie BW, Fleming RA, Russell GB, Rambo TD, Biesecker AC, Craven B. Quality of life and functional status after intraperitoneal hyperthermic chemotherapy (IPHC) for peritoneal carcinomatosis. Eur J Surg Oncol 2001; 27:65–73PubMedCrossRef
6.
Zurück zum Zitat McQuellon RP, Loggie BW, Lehman AB, Russell GB, Fleming RA, Shen P, Levine EA. Long-term survivorship and quality of life after cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. Ann Surg Oncol 2003; 10:155–62PubMedCrossRef McQuellon RP, Loggie BW, Lehman AB, Russell GB, Fleming RA, Shen P, Levine EA. Long-term survivorship and quality of life after cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. Ann Surg Oncol 2003; 10:155–62PubMedCrossRef
7.
Zurück zum Zitat Alexander R, Mavroukakis S, Libutti S, Pingpank J, Beresneva T, Marsden S, Steinberg S, Liewehr D. Impact of tumor resection (Rxn) and intraperitoneal (IP) chemotherapy (CHRx) on health related quality of life (HRQL) in patients (Pts) with peritoneal surface malignancies (PSM). In: Proceedings of the Society of Surgical Oncology 2005; S109 Alexander R, Mavroukakis S, Libutti S, Pingpank J, Beresneva T, Marsden S, Steinberg S, Liewehr D. Impact of tumor resection (Rxn) and intraperitoneal (IP) chemotherapy (CHRx) on health related quality of life (HRQL) in patients (Pts) with peritoneal surface malignancies (PSM). In: Proceedings of the Society of Surgical Oncology 2005; S109
8.
Zurück zum Zitat Loggie B, Fleming R, McQuellon R, Russell G, Geisinger K. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for disseminated peritoneal cancer of gastrointestinal origin. Am Surg 2000; 66:561–8PubMed Loggie B, Fleming R, McQuellon R, Russell G, Geisinger K. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for disseminated peritoneal cancer of gastrointestinal origin. Am Surg 2000; 66:561–8PubMed
9.
Zurück zum Zitat Ware JE, Jr, Snow KK, Kosinski M, Gandek B. SF-36 health survey. Manual and interpretation guide. Boston: Nimrod press; 1993 Ware JE, Jr, Snow KK, Kosinski M, Gandek B. SF-36 health survey. Manual and interpretation guide. Boston: Nimrod press; 1993
10.
Zurück zum Zitat McHorney CA, Ware JE Jr, Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993; 31:247–63PubMedCrossRef McHorney CA, Ware JE Jr, Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993; 31:247–63PubMedCrossRef
11.
Zurück zum Zitat Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singap 1994; 23:129–38PubMed Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singap 1994; 23:129–38PubMed
12.
Zurück zum Zitat Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1977; 1:385–401 Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1977; 1:385–401
13.
Zurück zum Zitat Katz MR, Kopek N, Waldron J, Devins GM, Tomlinson G. Screening for depression in head and neck cancer. Psychooncology 2004; 13:269–80PubMedCrossRef Katz MR, Kopek N, Waldron J, Devins GM, Tomlinson G. Screening for depression in head and neck cancer. Psychooncology 2004; 13:269–80PubMedCrossRef
14.
Zurück zum Zitat Husaini B, Neff J, Harrington J, Hughes M, Stone R. Depression in rural communities: validating the CES-D scale. J Commun Psychol 1980; 8:20–37 Husaini B, Neff J, Harrington J, Hughes M, Stone R. Depression in rural communities: validating the CES-D scale. J Commun Psychol 1980; 8:20–37
15.
Zurück zum Zitat Zubrod CG, Schneiderman M, Frei E, Brindley C, Gold GL, Shnider B, Orieto C, Gorman J, Jones R, Jonsson V, Colsky J, Chalmers T, Ferguson B, Dederick M, Holland J, Selawry O, Regelson W, Lasagna L, Owens AH. Appraisal of methods for the study of chemotherapy of cancer in man: comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide. J Chronic Dis 1960; 11:7–33CrossRef Zubrod CG, Schneiderman M, Frei E, Brindley C, Gold GL, Shnider B, Orieto C, Gorman J, Jones R, Jonsson V, Colsky J, Chalmers T, Ferguson B, Dederick M, Holland J, Selawry O, Regelson W, Lasagna L, Owens AH. Appraisal of methods for the study of chemotherapy of cancer in man: comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide. J Chronic Dis 1960; 11:7–33CrossRef
16.
Zurück zum Zitat Brucker PS, Yost K, Cashy J, Webster K, Cella D. General population and cancer patient norms for the functional assessment of cancer therapy-general (FACT-G). Eval Health Prof 2005; 28:192–211PubMedCrossRef Brucker PS, Yost K, Cashy J, Webster K, Cella D. General population and cancer patient norms for the functional assessment of cancer therapy-general (FACT-G). Eval Health Prof 2005; 28:192–211PubMedCrossRef
17.
Zurück zum Zitat Schmidt U, Dahlke MH, Klempnauer J, Schlitt HJ, Piso P. Perioperative morbidity and quality of life in long-term survivors following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol 2005; 31:53–8PubMedCrossRef Schmidt U, Dahlke MH, Klempnauer J, Schlitt HJ, Piso P. Perioperative morbidity and quality of life in long-term survivors following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol 2005; 31:53–8PubMedCrossRef
Metadaten
Titel
Monitoring Health Outcomes Following Cytoreductive Surgery Plus Intraperitoneal Hyperthermic Chemotherapy for Peritoneal Carcinomatosis
verfasst von
Richard P. McQuellon
Suzanne C. Danhauer
Gregory B. Russell
Perry Shen
Joyce Fenstermaker
John H. Stewart
Edward A. Levine
Publikationsdatum
01.03.2007
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 3/2007
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-006-9304-5

Weitere Artikel der Ausgabe 3/2007

Annals of Surgical Oncology 3/2007 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.